In light of its high efficiency and safety in phase I and phase II clinical trials, crizotinib has been granted accelerated approval by the Food and Drug Administration (FDA) as a front-line treatment for advanced ALK-rearranged NSCLC. The gene discussed is ALK; the disease is non-small cell lung carcinoma.